# Contact Research Peptides US — Editorial Desk

> Reach the Research Peptides US editorial desk regarding citations, corrections, or research-related correspondence about our research-peptide digest.

Correspondence on citations, corrections, and newly published research — the things a reference desk is actually useful to hear about.

## Editorial correspondence

Research Peptides US takes corrections seriously: a citation quoted inaccurately, a trial that has since published new results, a regulatory status update, or a peer-reviewed study on any of the five compounds that should be added to the [references page](/references). This is the single most useful class of message this desk receives, and every one is read.

The fastest-actioned submissions specify the exact page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier wherever possible — so the proposed change can be verified against its source before anything is edited.

**Editorial mailbox:** editors@researchpeptidesus.com

## What this desk cannot do

So no message goes unanswered for the wrong reason: Research Peptides US is a literature digest, not a clinical service or a vendor, so it cannot advise on human use of any compound discussed here, suggest a dose or schedule for any individual, evaluate whether a cited trial's findings apply to a specific person's situation, or sell, source, or help locate any compound from any supplier. It cannot advise athletes on anti-doping status for any compound.

Tirzepatide is a prescription medicine. Retatrutide is investigational and not legally available outside clinical trials. BPC-157 and KPV are unregulated research chemicals with no approved human use. Readers seeking medical guidance should consult a licensed clinician. Responses to editorial correspondence are not guaranteed and may be delayed.

---

A no-nonsense literature rundown on research peptides — straight evidence, no sales, no dosing advice.